Unlocking the potential of smart antibodies

By Yanay Ofran (Biolojic Design)2024-09-30T10:00:17

Biolojic Design is redefining antibody therapies by creating “programmable” antibodies that intelligently target well-validated autoimmune and oncology pathways. In this Q&A, CEO and founder Yanay Ofran, PhD, describes Biolojic’s groundbreaking approach, which leverages AI and machine learning to design antibodies capable of adjusting their behaviour based on their biological environment. ...

Already a member? Sign in

Unlock

Intelligence for the future of drug discovery

By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member